MPC-0920 Thrombosis Clinical Trial
Therapeutic Area: Thrombosis
Current Status: Phase 1
Phase 1 Clinical Trial
MPC-0920 is a new chemical entity with direct antithrombin
activity. This first in human study will characterize the safety,
tolerability and pharmacokinetic and pharmacodynamic properties of
this compound in a single ascending dose study in healthy
volunteers.
Contact
clinicaltrials@myriad.com
|
